The first data released today are anonymized, aggregated data of 10,000 human genomes (exomes) focused on hereditary breast and ovarian cancer. Ambry Genetics has already identified 10-fold more ...

Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics defeated an appeal by Myriad Genetics to block competing DNA-based tests to determine hereditary risk for breast and ovarian cancer after a ...

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. Tempus is a technology ...

Nancy Held already was battling breast cancer and recovering from a double mastectomy when a California lab, Ambry Genetics ... negative for BRCA, the gene mutation that drove actress Angelina ...

--(BUSINESS WIRE)--Ambry Genetics announced ... BRCA1/2 germline mutations are inherited in an autosomal dominant pattern. When mutated, the genetic alterations affect DNA repair leading to ...

Aliso Viejo-based Ambry Genetics Corp., Orange County’s third-largest medical diagnostics and testing company, has entered into an agreement to be acquired for $600 million by Tempus AI Inc., which is ...

several companies began to offer cheaper tests for the BRCA1 and BRCA2 mutations. Myriad and its partners in the suit says that even though the patents on the natural genes are invalidated, Gene by ...

Ambry Genetics has announced at the American College of Obstetricians ... Our 100 CF mutation panel includes only well defined disease causing mutations, without containing mild CF mutations like some ...